Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
2011

Comment on Capecitabine and Bevacizumab for Elderly Cancer Patients

Commentary

Author Information

Author(s): M J Molina-Garrido, C Guillén-Ponce

Primary Institution: Hospital Virgen de la Luz in Cuenca, Hospital Ramón y Cajal in Madrid

Hypothesis

The comprehensive geriatric assessment (CGA) should be used to evaluate elderly patients before cancer treatment.

Conclusion

The authors argue that the CGA is essential for assessing elderly patients' functional age and treatment tolerance.

Supporting Evidence

  • Elderly patients have a much higher cancer incidence and mortality risk compared to younger individuals.
  • The CGA can help identify elderly patients who are most vulnerable to complications from cancer treatments.
  • Studies show that the CGA is associated with treatment tolerance and outcomes in older cancer patients.

Takeaway

Doctors should use a special test to check how well older patients can handle cancer treatments, instead of just looking at their age.

Methodology

The commentary discusses the need for a comprehensive geriatric assessment (CGA) in elderly cancer patients.

Potential Biases

The reliance on subjective opinions in the original study may introduce bias.

Limitations

The commentary does not provide new data but critiques the existing study's methodology.

Participant Demographics

Elderly patients, specifically those aged 65 and older.

Digital Object Identifier (DOI)

10.1038/sj.bjc.6606037

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication